Get the app
US › Healthcare

ADC Therapeutics SA (ADCT)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$1.40-6.04%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$19.2M
Revenue YoY
+2.2%
Net profit
$-16.6M
EPS
$-0.11
EPS estimate
$-0.19
Net margin
-86.1%

EPS came in at -0.11 against a street estimate of -0.19 — a beat of 42.1%.

Key statistics

Market cap
$220.9M
Forward P/E
0.0
P/B
3.42
Book value
$-1.79
EPS (TTM)
$-0.65
52-week high
$4.98
52-week low
$0.78
50-day MA
$1.16
200-day MA
$2.64
Beta
1.86

Analyst view

Analysts rate ADC Therapeutics SA a buy (3 buy, 2 hold, 0 sell out of 5) with an average price target of $3.33.

Shareholding

Insiders
14.42%
Institutions
67.56%

Largest institutional holders

FundStake
Nantahala Capital Management, LLC19.31%
Redmile Group, LLC9.03%
TCG Crossover Management, LLC8.92%
Prosight Management, LP6.13%
BlackRock Inc5.50%
Morgan Stanley - Brokerage Accounts2.99%
Point72 Asset Management, L.P.2.86%
Millennium Management LLC2.27%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for ADC Therapeutics SA — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-19.